QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Breast Cancer Clinical Trial

Official title:

Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03127098
• Other study ID #: QUILT-3.040
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 26, 2017
• Est. completion date: December 7, 2017

Study information

• Verified date: August 2019
• Source: NantCell, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred after standard-of-care treatment.

Description:

The trial will consist of a phase 1b study with ETBX-011 as a fixed dose with a dose escalation of ALT-803 unless de-escalation is required. The proposed phase 2 expansion study will give additional safety data for the MTD as well as preliminary efficacy data. Subjects will receive treatments unless they experience progressive disease, dose-limiting toxicities (DLT), withdraw consent, or if the investigator determines it is no longer in their best medical interest to continue treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: December 7, 2017
• Est. primary completion date: December 7, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Age= 21 years.

2. Subjects with a histologically confirmed diagnosis of locally advanced or metastatic malignancy who were previously treated with at least one method of standard therapy known to have a possible survival benefit or refused such therapy.

3. The tumor must express CEA or must be known to be universally CEA positive (ie, colon and rectal cancer).

4. Must have a recent FFPE tumor biopsy specimen.

5. Subjects who have received prior CEA-targeted immunotherapy (eg, vaccine or antibody) are eligible for this trial if this treatment was discontinued at least 3 months prior to enrollment.

6. Resolution of all toxic side effects of prior chemotherapy, radiotherapy, or surgical procedures to NCI CTCAE grade = 1.

7. Ability to understand and provide signed informed consent that fulfills Institutional Review Board (IRB)'s guidelines.

8. ECOG performance status of 0 or 1.

9. Subjects who are taking medications that do not have a known history of immunosuppression are eligible for this trial.

10. Adequate hematologic function at screening, as follows:

11. WBC count = 3000/microliter.

12. Hemoglobin = 9 g/dL (may not transfuse or use erythropoietin to achieve this level).

13. Platelets = 75,000/microliter.

14. Prothrombin (PT)-international normalized ratio (INR) < 1.5.

15. Partial thromboplastin time (PTT) < 1.5 × upper limit of normal (ULN).

16. Adequate renal and hepatic function at screening, as follows:

17. Serum creatinine < 2.0 mg/dL.

18. Bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin = 2.0 mg/dL).

19. Alanine aminotransferase (ALT) = 2.5 × ULN.

20. Aspartate aminotransferase (AST) = 2.5 × ULN.

21. Female subjects of childbearing potential and women < 12 months since the onset of menopause must agree to use acceptable contraceptive methods for the duration of the study and for 7 months following the last injection of study medication. Male subjects must be surgically sterile or must agree to use a condom and acceptable contraceptive method with their partner.

22. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.

Exclusion Criteria:

1. Participation in an investigational drug or device study within 30 days of screening for this study.

2. Pregnant and nursing women.

3. Subjects with ongoing everolimus or other cancer therapy that interferes with the induction of immune responses.

4. Subjects with concurrent cytotoxic chemotherapy or radiation therapy. There must be at least one (1) month between any other prior chemotherapy (or radiotherapy) and study treatment. Any prior CEA-targeted immunotherapy (vaccine) must have been discontinued at least 3 months before initiation of study treatment. Subjects must have recovered from all acute toxicities from prior treatment prior to screening for this study.

5. Active brain or central nervous system metastasis, seizures requiring anticonvulsant treatment, cerebrovascular accident (< 6 months), or transient ischemic attack.

6. Subjects with a history of autoimmune disease (active or past), such as but not restricted to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune-related thyroid disease and vitiligo are permitted.

7. Subjects with serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, or other illness considered by the Investigator as high risk for investigational drug treatment.

8. Subjects with a history of heart disease, such as congestive heart failure (class II, III, or IV defined by the New York Heart Association functional classification), history of unstable or poorly controlled angina, or history (< 1 year) of ventricular arrhythmia.

9. Subjects with a medical or psychological impediment that would impair the ability of the subject to receive therapy per protocol or impact ability to comply with the protocol or protocol-required visits and procedures.

10. History of malignancy except for the following: adequately treated non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, or other carcinoma that has been in complete remission without treatment for more than 5 years.

11. Presence of a known active acute or chronic infection, including human immunodeficiency virus (HIV, as determined by enzyme-linked immunosorbent assay [ELISA] and confirmed by western blot) and hepatitis B and hepatitis C virus (HBV/HCV, as determined by HBsAg and hepatitis C serology).

12. Subjects on systemic intravenous or oral steroid therapy (or other immunosuppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Subjects must have had at least 6 weeks of discontinuation of any steroid therapy (except that used as premedication for chemotherapy or contrast-enhanced studies) prior to enrollment.

13. Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded.

14. Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.

15. Subjects vaccinated with a live (attenuated) vaccine (e.g., FluMist®) or a killed (inactivated)/subunit vaccine (e.g., PNEUMOVAX®, Fluzone®) within 28 days or 14 days, respectively, of the first planned dose of ETBX-011 or ALT 803.

Related Conditions & MeSH terms

• Breast Cancer
• Colon Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Thyroid Cancer
• Thyroid Neoplasms

Intervention

Biological:
• ETBX-011
ETBX-011 immunization will be administered by subcutaneous (SC) injection.
• ALT-803
ALT-803 will be administered by SC injection.

Locations

Country	Name	City	State
United States	Medical Oncology Associates	Spokane	Washington

Sponsors (1)

Lead Sponsor	Collaborator
NantCell, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicities and maximum tolerated dose of the ETBX-011 plus ALT-803 combination treatment. (Phase 1b)		11 weeks
Primary	Overall treatment-emergent AEs and SAEs [safety and tolerability] and preliminarily evaluate Objective response rate (ORR). (Phase 2)		1 year
Secondary	Preliminarily evaluate Duration of Response (DoR)		1 year
Secondary	Preliminarily evaluate Progressive-free survival (PFS)		1 year
Secondary	Preliminarily evaluate Overall Survival (OS)		1 year